MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
3. Government_Funders & Regulators
Government: Roles
Funders
Funding: U.S. Federal
*Funding: HHS
*HHS: Contracts, Contractors & Awards
*BARDA: Contracts (IDIQ, GWACS, Etc.), Contractors & Awardees
*Contractors & Awardees: BARDA
PlateletBio
Attachments
PlateletBio
Parents
*Architects: BioPharmaceuticals_Inflammation, Allergy & Autoimmune
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
*Contractors & Awardees: BARDA
*Industry: Massachusetts
Architects: Rheumatology _ Arthritis, Fibromyalgia
Children
2021: PlateletBio announces $75.5M Series B to extend autoimmune cell therapy
2021: The round was led by new investors SymBiosis, K2 HealthVentures, and Oxford Finance, and already-existing investors
CEO Sam Rasty, PlateletBio (2021)
Preclinical development of its lead platelet-like cell program as a therapy for the autoimmune disease immune throbocytopenia.
The company is working to advance its pipeline of therapies for autoimmune diseases, hematology and inflammation.
Watertown, Massachusetts
Jumps
Harvard University